



Botulinum Toxins

HMSA Medicare Advantage - Prior Authorization Request

CVS Caremark administers the prescription benefit plan for the patient identified. This patient's benefit plan requires prior authorization for certain medications in order for the drug to be covered. To make an appropriate determination, providing the most accurate diagnosis for the use of the prescribed medication is necessary. **Please respond below and fax this form to CVS Caremark toll-free at 1-866-237-5512.** If you have questions regarding the prior authorization, please contact CVS Caremark at **1-808-254-4414**. For inquiries or questions related to the patient's eligibility, drug copay or medication delivery; please contact the Specialty Customer Care Team: CaremarkConnect® 1-800-237-2767.

The recipient of this fax may make a request to opt-out of receiving telemarketing fax transmissions from CVS Caremark. There are numerous ways you may opt-out: The recipient may call the toll-free number at 877-265-2711, at any time, 24 hours a day/7 days a week. The recipient may also send an opt-out request via email to do_not_call@cvscaremark.com. An opt out request is only valid if it (1) identifies the number to which the request relates, and (2) if the person/entity making the request does not, subsequent to the request, provide express invitation or permission to CVS Caremark to send facsimile advertisements to such person/entity at that particular number. CVS Caremark is required by law to honor an opt-out request within thirty days of receipt.

Patient's Name: _____ **Date:** _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Patient's Phone Number: _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Additional Demographic Information:

Patient Weight: _____ *kg*
Patient Height: _____ *ft* _____ *inches*

Indicate where the drug is being dispensed:

- Office Outpatient Hospital Ambulatory Surgical Inpatient Hospital
- Off Campus Outpatient Hospital Urgent Care Emergency Room Birthing Center
- Military Facility Skilled Nursing Facility Nursing Facility Hospice
- Inpatient Psychiatric Psychiatric Residential Treatment End Stage Renal Facility
- Psychiatric Facility Pharmacy Other

Indicate where the drug is being administered:

- Ambulatory surgical Home Inpatient Hospital
- Office Outpatient Hospital Pharmacy

What is the ICD-10 code? _____

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com

Exception Criteria Questions:

- A. What is the drug being prescribed?
- Botox, *Continue to Question B*
 - Daxxify, *Continue to Question B*
 - Dysport *Skip to Clinical Criteria Questions*
 - Myobloc, *Continue to Question B*
 - Xeomin *Skip to Clinical Criteria Questions*
- B. Is the product being requested for the treatment of one of the following indications?
- Cervical dystonia in adults
 - Chronic sialorrhea in adults
 - Blepharospasm in members 12 years of age and older
 - Spasticity
- Yes, *Continue to Question C*
 No, *Skip to Clinical Criteria Questions*
- C. The preferred products for your patient's health plan are Dysport and Xeomin.
Can the patient's treatment be switched to a preferred product?
- Yes – Dysport, *Skip to Clinical Criteria Questions*
 - Yes – Xeomin, *Skip to Clinical Criteria Questions*
 - No, *Continue to Question D*
- D. Has the patient received treatment with the requested product in the past 365 days?
- Yes, *Skip to Clinical Criteria Questions*
 - No, *Continue to Question E*
- E. Is the request for cervical dystonia?
- Yes, *Continue to Question F*
 - No *Skip to Question G*
- F. Has the patient had a documented inadequate response or intolerable adverse event to treatment with both of the preferred products (Dysport and Xeomin)? **Action required: If 'Yes', Attach supporting chart note(s).**
- Yes, *Skip to Clinical Criteria Questions*
 - No *Skip to Clinical Criteria Questions*
- G. Is the request for Myobloc to treat chronic sialorrhea?
- Yes, *Continue to Question H*
 - No *Skip to Question I*
- H. Has the patient experienced a documented inadequate response or intolerable adverse event to treatment with the preferred product (Xeomin)? **Action required: If 'Yes', Attach supporting chart note(s).**
- Yes, *Skip to Clinical Criteria Questions*
 - No *Skip to Clinical Criteria Questions*
- I. Is the request for Botox for the treatment of blepharospasm in a patient 12 years of age or older but less than 18 years of age?
- Yes, *Skip to Clinical Criteria Questions*
 - No, *Continue to Question J*
- J. Is the request for Botox for the treatment of blepharospasm in a patient 18 years of age or older?
- Yes, *Continue to Question K*
 - No *Skip to Question L*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

- K. Has the patient had a documented inadequate response or intolerable adverse event to treatment with Xeomin?
Action required: If 'Yes', Attach supporting chart note(s).
 Yes, Skip to Clinical Criteria Questions
 No Skip to Clinical Criteria Questions
- L. Is the request for Botox for the treatment of lower limb spasticity?
 Yes, Continue to Question M
 No Skip to Question N
- M. Has the patient had a documented inadequate response or intolerable adverse event to treatment with Dysport?
Action Required: If 'Yes', Attach supporting chart note(s).
 Yes, Skip to Clinical Criteria Questions
 No Skip to Clinical Criteria Questions
- N. Has the patient had a documented inadequate response or intolerable adverse event to treatment with both preferred products (Dysport and Xeomin)? **Action Required: If 'Yes', Attach supporting chart note(s).**
 Yes, Skip to Clinical Criteria Questions
 No, Continue to Question O
- O. Is the request for Botox to treat upper limb spasticity in pediatric patient who is at least 2 years old and less than 18 years old and the upper limb spasticity is due to cerebral palsy?
 Yes, Continue to Question P
 No, Continue to Question P
- P. Has the patient had a documented inadequate response or intolerable adverse event to treatment with Dysport?
Action Required: If 'Yes', Attach supporting chart note(s).
 Yes, Continue to Clinical Criteria Questions
 No, Continue to Clinical Criteria Questions

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

Clinical Criteria Questions:

1. Is botulinum toxin prescribed for a cosmetic indication or any other condition or ICD-10 code listed in Appendix D (Conditions for Which Botulinum Toxin Therapy is NOT Reasonable and Necessary)?

- Yes, *Continue to #2*
 No, *Continue to #2*

2. Is botulinum toxin prescribed for a patient with ANY of the ICD-10 codes listed in Appendix C, Table 1: ICD-10 Codes That Support Medical Necessity That May Be Used Alone?

- Yes, *Continue to #5*
 No, *Continue to #3*

3. Is botulinum toxin prescribed for a patient with ANY of the ICD-10 codes listed in Appendix C, Table 2: Primary ICD-10 Codes That Support Medical Necessity and Require a Secondary ICD-10 Code for Payment?

- Yes, *Continue to #4*
 No, *No Further Questions*

4. Do ANY of the ICD-10 codes listed in Appendix C, Table 3: Secondary ICD-10 Codes ALSO apply to the patient?

- Yes, *Continue to #5*
 No, *No Further Questions*

Botulinum Toxin Products and FDA-Approved Indications

5. Is botulinum toxin prescribed for any of the following conditions or indications?

- Overactive bladder
- Urinary incontinence associated with a neurologic condition (e.g., spinal cord injury, multiple sclerosis)
- Prophylaxis of chronic migraine headaches
- Severe primary axillary hyperhidrosis
- Strabismus

- Yes, *Continue to #6*
 No, *Continue to #7*

6. Which is the prescribed botulinum toxin product?

- Botox, *Continue to #14*
 Dysport, *Continue to #13*
 Xeomin, *Continue to #13*
 Myobloc, *Continue to #13*
 Daxxify, *Continue to #13*

7. Is botulinum toxin prescribed for upper limb spasticity?

- Yes, *Continue to #8*
 No, *Continue to #9*

8. Which is the prescribed botulinum toxin product?

- Botox, *Continue to #14*
 Dysport, *Continue to #14*
 Xeomin, *Continue to #14*
 Myobloc, *Continue to #13*
 Daxxify, *Continue to #13*

9. Is botulinum toxin prescribed for lower limb spasticity?

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

- Yes, *Continue to #10*
 No, *Continue to #11*

10. Which is the prescribed botulinum toxin product?

- Botox, *Continue to #14*
 Dysport, *Continue to #14*
 Xeomin, *Continue to #13*
 Myobloc, *Continue to #13*
 Daxxify, *Continue to #13*

11. Is botulinum toxin prescribed for blepharospasm?

- Yes, *Continue to #12*
 No, *Continue to #14*

12. Which is the prescribed botulinum toxin product?

- Botox, *Continue to #14*
 Dysport, *Continue to #13*
 Xeomin, *Continue to #14*
 Myobloc, *Continue to #13*
 Daxxify, *Continue to #13*

13. Is there a valid and documented reason why the prescriber is not using a botulinum toxin product that is approved by the FDA to treat the patient's diagnosis or indication?

- Yes, *Continue to #14*
 No, *Continue to #14*

Diagnoses and Requirements

14. Is botulinum toxin prescribed for overactive bladder?

- Yes, *Continue to #15*
 No, *Continue to #16*

15. Has the patient tried but experienced an inadequate response or intolerance to anticholinergic medication?

- Yes, *Continue to #22*
 No, *Continue to #22*

16. Is botulinum toxin prescribed for any of the following conditions?

- Focal dystonia
- Hemifacial spasm
- Orofacial dyskinesia
- Blepharospasm
- Severe writer's cramp
- Laryngeal spasm
- Dysphonia

- Yes, *Continue to #22*
 No, *Continue to #17*

17. Has the patient tried but experienced an inadequate response to conventional treatment such as traditional medications, physical therapy and other appropriate methods?

- Yes, *Continue to #18*

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com

No, *Continue to #18*

18. Is botulinum toxin prescribed for achalasia and cardiospasm (ICD-10 code K22.0)?

Yes, *Continue to #19*

No, *Continue to #20*

19. Does the patient meet at least one of the following criteria?

- The patient has failed conventional therapy
- The patient is at high risk of complications from pneumatic dilation or surgical myotomy
- The patient refuses surgical myotomy or balloon dilation, in preference to a less invasive risky procedure
- A prior myotomy or dilatation has failed
- A prior dilatation caused an esophageal perforation
- The patient has an epiphrenic diverticulum or hiatal hernia, both of which increase the risk of dilatation-induced perforation

Yes, *Continue to #22*

No, *Continue to #22*

20. Is botulinum toxin prescribed for prophylaxis of chronic migraine headaches?

Yes, *Continue to #21*

No, *Continue to #22*

21. Is the patient an adult who was diagnosed with chronic migraine (headaches on at least 15 days per month lasting at least 4 hours per day)?

Yes, *Continue to #25*

No, *Continue to #25*

Approval Duration/Continuation Criteria

22. Has the patient previously received treatment with botulinum toxin for his/her condition or indication?

Yes, *Continue to #23*

No, *No Further Questions*

23. Has the patient experienced a satisfactory clinical response to botulinum toxin therapy?

Yes, *No Further Questions*

No, *Continue to #24*

24. Have 2 or more treatments in a row with one product, plus 1 treatment with an alternative product, both at the maximum appropriate dose, failed to produce a satisfactory clinical response?

Yes, *No Further Questions*

No / not applicable, *No Further Questions*

25. Has the patient previously received treatment with botulinum toxin for prophylaxis of chronic migraine headaches?

Yes, *Continue to #26*

No, *No Further Questions*

26. Has the patient experienced a satisfactory clinical response to botulinum toxin therapy?

Yes, *No Further Questions*

No, *Continue to #27*

27. Have 2 or more treatments in a row with one product, plus 1 treatment with an alternative product, both at the

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819

Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com

maximum appropriate dose, failed to produce a satisfactory clinical response?

Yes, *No Further Questions*

No / not applicable, *No Further Questions*

APPENDICES

Appendix A: Botulinum toxin HCPCS Codes

J0585	INJECTION, ONABOTULINUMTOXINA, 1 UNIT
J0586	INJECTION, ABOBOTULINUMTOXINA, 5 UNITS
J0587	INJECTION, RIMABOTULINUMTOXINB, 100 UNITS
J0588	INJECTION, INCOBOTULINUMTOXIN A, 1 UNIT
J0589	INJECTION, DAXIBOTULINUMTOXINA-LANM, 1 UNIT

Appendix B: Procedure Codes That Support Medical Necessity

The following CPT codes are to be reported for the procedures performed:

31513 [†]	LARYNGOSCOPY, INDIRECT; WITH VOCAL CORD INJECTION
31570 [†]	LARYNGOSCOPY, DIRECT, WITH INJECTION INTO VOCAL CORD(S), THERAPEUTIC;
43201 [†]	ESOPHAGOSCOPY, FLEXIBLE, TRANSORAL; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE
43236 [†]	ESOPHAGOGASTRODUODENOSCOPY, FLEXIBLE, TRANSORAL; WITH DIRECTED SUBMUCOSAL INJECTION(S), ANY SUBSTANCE
43499 [†]	UNLISTED PROCEDURE, ESOPHAGUS
46505*	CHEMODENERVATION OF INTERNAL ANAL SPHINCTER
52287*	CYSTOURETHROSCOPY, WITH INJECTION(S) FOR CHEMODENERVATION OF THE BLADDER
64611*	CHEMODENERVATION OF PAROTID AND SUBMANDIBULAR SALIVARY GLANDS, BILATERAL
64612*	CHEMODENERVATION OF MUSCLE(S); MUSCLE(S) INNERVATED BY FACIAL NERVE, UNILATERAL (EG, FOR BLEPHAROSPASM, HEMIFACIAL SPASM)
64615*	CHEMODENERVATION OF MUSCLE(S); MUSCLE(S) INNERVATED BY FACIAL, TRIGEMINAL, CERVICAL SPINAL AND ACCESSORY NERVES, BILATERAL (EG, FOR CHRONIC MIGRAINE)
64616*	CHEMODENERVATION OF MUSCLE(S); NECK MUSCLE(S), EXCLUDING MUSCLES OF THE LARYNX, UNILATERAL (EG, FOR CERVICAL DYSTONIA, SPASMODIC TORTICOLLIS)
64617*	CHEMODENERVATION OF MUSCLE(S); LARYNX, UNILATERAL, PERCUTANEOUS (EG, FOR SPASMODIC DYSPHONIA), INCLUDES GUIDANCE BY NEEDLE ELECTROMYOGRAPHY, WHEN PERFORMED
64640 [†]	DESTRUCTION BY NEUROLYTIC AGENT; OTHER PERIPHERAL NERVE OR BRANCH
64642*	CHEMODENERVATION OF ONE EXTREMITY; 1-4 MUSCLE(S)
64643*	CHEMODENERVATION OF ONE EXTREMITY; EACH ADDITIONAL EXTREMITY, 1-4 MUSCLE(S) (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
64644*	CHEMODENERVATION OF ONE EXTREMITY; 5 OR MORE MUSCLE

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819

Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com

64645*	CHEMODENERVATION OF ONE EXTREMITY; EACH ADDITIONAL EXTREMITY, 5 OR MORE MUSCLE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
64646*	CHEMODENERVATION OF TRUNK MUSCLE(S); 1-5 MUSCLE(S)
64647*	CHEMODENERVATION OF TRUNK MUSCLE(S); 6 OR MORE MUSCLE
64650*	CHEMODENERVATION OF ECCRINE GLANDS; BOTH AXILLAE
64653*	CHEMODENERVATION OF ECCRINE GLANDS; OTHER AREA(S) (EG, SCALP, FACE, NECK), PER DAY
64999†	UNLISTED PROCEDURE, NERVOUS SYSTEM
67345*	CHEMODENERVATION OF EXTRAOCULAR MUSCLE
95873*	ELECTRICAL STIMULATION FOR GUIDANCE IN CONJUNCTION WITH CHEMODENERVATION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
95874*	NEEDLE ELECTROMYOGRAPHY FOR GUIDANCE IN CONJUNCTION WITH CHEMODENERVATION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

* Refer to the ICD-10 codes in Appendix C that support medical necessity (Tables 1-3).

† Not restricted by the ICD-10 codes listed in this policy.

Appendix C: ICD-10-CM Codes That Support Medical Necessity

These are the only ICD-10-CM codes that support medical necessity for CPT/HCPCS codes J0585, J0586, J0587, J0588, 46505, 52287, 64611, 64612, 64615, 64616, 64617, 64642, 64643, 64644, 64645, 64646, 64647, 64650, 64653, 67345, 95873, 95874.

The following CPT codes are not restricted by the ICD-10-CM codes listed in this policy: 31513, 31570, 43201, 43236, 43499, 53899, 64640 and 64999.

The following ICD-10-CM codes may be used alone:

Table 1: ICD-10-CM Codes for Botulinum Toxin That That Support Medical Necessity and May be Used Alone

ICD-10 CODE	DESCRIPTION
G11.4	Hereditary spastic paraplegia
G24.1	Genetic torsion dystonia
G24.2	Idiopathic nonfamilial dystonia
G24.3	Spasmodic torticollis
G24.4	Idiopathic orofacial dystonia
G24.5	Blepharospasm
G24.8	Other dystonia
G24.9	Dystonia, unspecified
G25.3	Myoclonus
G25.89	Other specified extrapyramidal and movement disorders
G36.1	Acute and subacute hemorrhagic leukoencephalitis [Hurst]
G36.8	Other specified acute disseminated demyelination
G37.0	Diffuse sclerosis of central nervous system
G37.1	Central demyelination of corpus callosum
G37.2	Central pontine myelinolysis
G37.4	Subacute necrotizing myelitis of central nervous system

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

G37.5	Concentric sclerosis [Balo] of central nervous system
G37.8	Other specified demyelinating diseases of central nervous system
G37.9	Demyelinating disease of central nervous system, unspecified
G43.011	Migraine without aura, intractable, with status migrainosus
G43.019	Migraine without aura, intractable, without status migrainosus
G43.109	Migraine with aura, not intractable, without status migrainosus
G43.111	Migraine with aura, intractable, with status migrainosus
G43.119	Migraine with aura, intractable, without status migrainosus
G43.701	Chronic migraine without aura, not intractable, with status migrainosus
G43.709	Chronic migraine without aura, not intractable, without status migrainosus
G43.711	Chronic migraine without aura, intractable, with status migrainosus
G43.719	Chronic migraine without aura, intractable, without status migrainosus
G44.221	Chronic tension-type headache, intractable
G44.229	Chronic tension-type headache, not intractable
G50.8	Other disorders of trigeminal nerve
G51.2	Melkersson's syndrome
G51.31	Clonic hemifacial spasm, right
G51.32	Clonic hemifacial spasm, left
G51.33	Clonic hemifacial spasm, bilateral
G51.4	Facial myokymia
G51.8	Other disorders of facial nerve
G80.0	Spastic quadriplegic cerebral palsy
G80.1	Spastic diplegic cerebral palsy
G80.2	Spastic hemiplegic cerebral palsy
G80.4	Ataxic cerebral palsy
G80.8	Other cerebral palsy
G82.53	Quadriplegia, C5-C7 complete
G83.0*	Diplegia of upper limbs
G83.11*	Monoplegia of lower limb affecting right dominant side
G83.12*	Monoplegia of lower limb affecting left dominant side
G83.13*	Monoplegia of lower limb affecting right nondominant side
G83.14*	Monoplegia of lower limb affecting left nondominant side
G83.21	Monoplegia of upper limb affecting right dominant side
G83.22	Monoplegia of upper limb affecting left dominant side
G83.23	Monoplegia of upper limb affecting right nondominant side
G83.24	Monoplegia of upper limb affecting left nondominant side
G83.4	Cauda equina syndrome
H02.041	Spastic entropion of right upper eyelid
H02.042	Spastic entropion of right lower eyelid
H02.044	Spastic entropion of left upper eyelid
H02.045	Spastic entropion of left lower eyelid
H02.141	Spastic entropion of right upper eyelid
H02.142	Spastic entropion of right lower eyelid
H02.144	Spastic entropion of left upper eyelid
H02.145	Spastic entropion of left lower eyelid
H04.213	Epiphora due to excess lacrimation, bilateral lacrimal glands
H49.01	Third [oculomotor] nerve palsy, right eye
H49.02	Third [oculomotor] nerve palsy, left eye
H49.03	Third [oculomotor] nerve palsy, bilateral
H49.11	Fourth [trochlear] nerve palsy, right eye

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

H49.12	Fourth [trochlear] nerve palsy, left eye
H49.13	Fourth [trochlear] nerve palsy, bilateral
H49.21	Sixth [abducent] nerve palsy, right eye
H49.22	Sixth [abducent] nerve palsy, left eye
H49.23	Sixth [abducent] nerve palsy, bilateral
H49.31	Total (external) ophthalmoplegia, right eye
H49.32	Total (external) ophthalmoplegia, left eye
H49.33	Total (external) ophthalmoplegia, bilateral
H49.41	Progressive external ophthalmoplegia, right eye
H49.42	Progressive external ophthalmoplegia, left eye
H49.43	Progressive external ophthalmoplegia, bilateral
H49.881	Other paralytic strabismus, right eye
H49.882	Other paralytic strabismus, left eye
H49.883	Other paralytic strabismus, bilateral
H49.9	Unspecified paralytic strabismus
H50.00	Unspecified esotropia
H50.011	Monocular esotropia, right eye
H50.012	Monocular esotropia, left eye
H50.021	Monocular esotropia with A pattern, right eye
H50.022	Monocular esotropia with A pattern, left eye
H50.031	Monocular esotropia with V pattern, right eye
H50.032	Monocular esotropia with V pattern, left eye
H50.041	Monocular esotropia with other noncomitancies, right eye
H50.042	Monocular esotropia with other noncomitancies, left eye
H50.05	Alternating esotropia
H50.06	Alternating esotropia with A pattern
H50.07	Alternating esotropia with V pattern
H50.08	Alternating esotropia with other noncomitancies
H50.10	Unspecified exotropia
H50.111	Monocular exotropia, right eye
H50.112	Monocular exotropia, left eye
H50.121	Monocular exotropia with A pattern, right eye
H50.122	Monocular exotropia with A pattern, left eye
H50.131	Monocular exotropia with V pattern, right eye
H50.132	Monocular exotropia with V pattern, left eye
H50.141	Monocular exotropia with other noncomitancies, right eye
H50.142	Monocular exotropia with other noncomitancies, left eye
H50.15	Alternating exotropia
H50.16	Alternating exotropia with A pattern
H50.17	Alternating exotropia with V pattern
H50.18	Alternating exotropia with other noncomitancies
H50.21	Vertical strabismus, right eye
H50.22	Vertical strabismus, left eye
H50.311	Intermittent monocular esotropia, right eye
H50.312	Intermittent monocular esotropia, left eye
H50.32	Intermittent alternating esotropia
H50.331	Intermittent monocular exotropia, right eye
H50.332	Intermittent monocular exotropia, left eye
H50.34	Intermittent alternating exotropia
H50.411	Cyclotropia, right eye

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

H50.412	Cyclotropia, left eye
H50.42	Monofixation syndrome
H50.43	Accommodative component in esotropia
H50.51	Esophoria
H50.52	Exophoria
H50.53	Vertical heterophoria
H50.54	Cyclophoria
H50.55	Alternating heterophoria
H50.611	Brown's sheath syndrome, right eye
H50.612	Brown's sheath syndrome, left eye
H50.69	Other mechanical strabismus
H50.811*	Duane's syndrome, right eye
H50.812*	Duane's syndrome, left eye
H50.89	Other specified strabismus
H51.0	Palsy (spasm) of conjugate gaze
H51.11	Convergence insufficiency
H51.12	Convergence excess
H51.21	Internuclear ophthalmoplegia, right eye
H51.22	Internuclear ophthalmoplegia, left eye
H51.23	Internuclear ophthalmoplegia, bilateral
H51.8	Other specified disorders of binocular movement
I69.364	Other paralytic syndrome following cerebral infarction affecting left non-dominant side
I69.365	Other paralytic syndrome following cerebral infarction, bilateral
I69.831	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
I69.832	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
I69.931	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right dominant side
I69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
I69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side
I69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
I69.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side
I69.951	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right dominant side
I69.952	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left dominant side
I69.953	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting right non-dominant side
I69.954	Hemiplegia and hemiparesis following unspecified cerebrovascular disease affecting left non-dominant side
J38.3	Other diseases of vocal cords
J38.5	Laryngeal spasm
J39.2	Other diseases of pharynx
K11.7	Disturbances of salivary secretion
K22.0*	Achalasia of cardia
K60.0	Acute anal fissure
K60.1	Chronic anal fissure
L74.510	Primary focal hyperhidrosis, axilla
L74.511	Primary focal hyperhidrosis, face
L74.512	Primary focal hyperhidrosis, palms
L74.513	Primary focal hyperhidrosis, soles

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

L74.52	Secondary focal hyperhidrosis
N31.0*	Uninhibited neuropathic bladder, not elsewhere classified
N31.1*	Reflex neuropathic bladder, not elsewhere classified
N31.8	Other neuromuscular dysfunction of bladder
N31.9*	Neuromuscular dysfunction of bladder, unspecified
N32.81	Overactive bladder
N36.44	Muscular disorders of urethra
N39.41	Urge incontinence
N39.46	Mixed incontinence
N39.498	Other specified urinary incontinence
R49.8	Other voice and resonance disorders

* K22.0 CPT code 43499 is to be billed with K22.00, but K22.0 may be billed with other appropriate CPT codes too. Please refer to Coverage Indications, Limitations and/or Medical Necessity.

* H50.811, H50.812, use for medial rectus weakness only (refer to Appendix D for lateral rectal muscle weakness).

* G83.0; G83.11; G83.12; G83.13; G83.14; N31.0; N31.1; N31.9 require a second code from Group 2 in order to be payable.

[Internal note: there is a discrepancy for G83.0; G83.11; G83.12; G83.13; G83.14; N31.0; N31.1; N31.9 in the asterisk explanation and placement in Table 1.]

The following ICD-10 codes must be used in pairs, i.e., one primary diagnosis and one secondary diagnosis.

Primary diagnosis codes:

Table 2: Primary ICD-10 Codes That Support Medical Necessity and Require a Secondary ICD-10 Code for Payment

ICD-10 CODE	DESCRIPTION
G36.1*	Acute and subacute hemorrhagic leukoencephalitis [Hurst]
G51.31*	Clonic hemifacial spasm, right
G51.32*	Clonic hemifacial spasm, left
G51.33*	Clonic hemifacial spasm, bilateral
G80.3*	Athetoid cerebral palsy
G82.51*	Quadriplegia, C1-C4 complete
G82.52*	Quadriplegia, C1-C4 incomplete
G82.53*	Quadriplegia, C5-C7 complete
G83.82*	Anterior cord syndrome
G83.89*	Other specified paralytic syndromes
M62.411*	Contracture of muscle, right shoulder
M62.412*	Contracture of muscle, left shoulder
M62.421*	Contracture of muscle, right upper arm
M62.422*	Contracture of muscle, left upper arm
M62.431*	Contracture of muscle, right forearm
M62.432*	Contracture of muscle, left forearm
M62.441*	Contracture of muscle, right hand
M62.442*	Contracture of muscle, left hand
M62.451*	Contracture of muscle, right thigh
M62.452*	Contracture of muscle, left thigh
M62.461*	Contracture of muscle, right lower leg
M62.462*	Contracture of muscle, left lower leg
M62.471*	Contracture of muscle, right ankle and foot
M62.472*	Contracture of muscle, left ankle and foot

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

M62.48*	Contracture of muscle, other site
M62.49*	Contracture of muscle, multiple sites
M62.831*	Muscle spasm of calf
M62.838*	Other muscle spasm

* The diagnosis codes above require a second code from the table below in order to be payable.

Secondary diagnosis codes:

Table 3: Secondary ICD-10 Codes

ICD-10 CODE	DESCRIPTION
G04.1*	Tropical spastic paraplegia
G35*	Multiple sclerosis
G81.11*	Spastic hemiplegia affecting right dominant side
G81.12*	Spastic hemiplegia affecting left dominant side
G81.13*	Spastic hemiplegia affecting right nondominant side
G81.14*	Spastic hemiplegia affecting left nondominant side
G82.21*	Paraplegia, complete
G82.22*	Paraplegia, incomplete
G82.50*	Quadriplegia, unspecified
G82.54*	Quadriplegia, C5-C7 incomplete
G93.40*	Encephalopathy, unspecified
G95.89*	Other specified diseases of spinal cord
G97.2*	Intracranial hypotension following ventricular shunting
G97.31*	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating a nervous system procedure
G97.32*	Intraoperative hemorrhage and hematoma of a nervous system organ or structure complicating other procedure
G97.81*	Other intraoperative complications of nervous system
G97.82*	Other postprocedural complications and disorders of nervous system
I60.01*	Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02*	Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.11*	Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12*	Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2*	Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.31*	Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32*	Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4*	Nontraumatic subarachnoid hemorrhage from basilar artery
I60.51*	Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52*	Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6*	Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.8*	Other nontraumatic subarachnoid hemorrhage
I61.0*	Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1*	Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.3*	Nontraumatic intracerebral hemorrhage in brain stem
I61.4*	Nontraumatic intracerebral hemorrhage in cerebellum
I61.5*	Nontraumatic intracerebral hemorrhage, intraventricular
I61.6*	Nontraumatic intracerebral hemorrhage, multiple localized
I61.8*	Other nontraumatic intracerebral hemorrhage
I62.01*	Nontraumatic acute subdural hemorrhage
I62.02*	Nontraumatic subacute subdural hemorrhage

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I62.03*	Nontraumatic chronic subdural hemorrhage
I62.1*	Nontraumatic extradural hemorrhage
I63.011*	Cerebral infarction due to thrombosis of right vertebral artery
I63.012*	Cerebral infarction due to thrombosis of left vertebral artery
I63.013*	Cerebral infarction due to thrombosis of bilateral vertebral arteries
I63.02*	Cerebral infarction due to thrombosis of basilar artery
I63.031*	Cerebral infarction due to thrombosis of right carotid artery
I63.032*	Cerebral infarction due to thrombosis of left carotid artery
I63.033*	Cerebral infarction due to thrombosis of bilateral carotid arteries
I63.09*	Cerebral infarction due to thrombosis of other precerebral artery
I63.111*	Cerebral infarction due to embolism of right vertebral artery
I63.112*	Cerebral infarction due to embolism of left vertebral artery
I63.113*	Cerebral infarction due to embolism of bilateral vertebral arteries
I63.12*	Cerebral infarction due to embolism of basilar artery
I63.133*	Cerebral infarction due to embolism of bilateral carotid arteries
I63.19*	Cerebral infarction due to embolism of other precerebral artery
I63.211*	Cerebral infarction due to unspecified occlusion or stenosis of right vertebral artery
I63.212	Cerebral infarction due to unspecified occlusion or stenosis of left vertebral artery
I63.213*	Cerebral infarction due to unspecified occlusion or stenosis of bilateral vertebral arteries
I63.233*	Cerebral infarction due to unspecified occlusion or stenosis of bilateral carotid arteries
I63.311*	Cerebral infarction due to thrombosis of right middle cerebral artery
I63.312*	Cerebral infarction due to thrombosis of left middle cerebral artery
I63.313*	Cerebral infarction due to thrombosis of bilateral middle cerebral arteries
I63.321*	Cerebral infarction due to thrombosis of right anterior cerebral artery
I63.322*	Cerebral infarction due to thrombosis of left anterior cerebral artery
I63.323*	Cerebral infarction due to thrombosis of bilateral anterior cerebral arteries
I63.331*	Cerebral infarction due to thrombosis of right posterior cerebral artery
I63.332*	Cerebral infarction due to thrombosis of left posterior cerebral artery
I63.333	Cerebral infarction due to thrombosis of bilateral posterior cerebral arteries
I63.341*	Cerebral infarction due to thrombosis of right cerebellar artery
I63.342*	Cerebral infarction due to thrombosis of left cerebellar artery
I63.343*	Cerebral infarction due to thrombosis of bilateral cerebellar arteries
I63.39*	Cerebral infarction due to thrombosis of other cerebral artery
I63.411*	Cerebral infarction due to embolism of right middle cerebral artery
I63.412*	Cerebral infarction due to embolism of left middle cerebral artery
I63.421*	Cerebral infarction due to embolism of right anterior cerebral artery
I63.422*	Cerebral infarction due to embolism of left anterior cerebral artery
I63.431*	Cerebral infarction due to embolism of right posterior cerebral artery
I63.432*	Cerebral infarction due to embolism of left posterior cerebral artery
I63.441*	Cerebral infarction due to embolism of right cerebellar artery
I63.442*	Cerebral infarction due to embolism of left cerebellar artery
I63.49*	Cerebral infarction due to embolism of other cerebral artery
I63.513*	Cerebral infarction due to unspecified occlusion or stenosis of bilateral middle cerebral arteries
I63.523*	Cerebral infarction due to unspecified occlusion or stenosis of bilateral anterior cerebral arteries
I63.533*	Cerebral infarction due to unspecified occlusion or stenosis of bilateral posterior cerebral arteries
I63.6*	Cerebral infarction due to cerebral venous thrombosis, nonpyogenic
I63.81*	Other cerebral infarction due to occlusion or stenosis of small artery (Other cerebral infarction due to occlusion or stenosis of small artery)
I63.89*	Other cerebral infarction

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I69.031*	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.032*	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.033*	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.034*	Monoplegia of upper limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.041*	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.042*	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.043*	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.044*	Monoplegia of lower limb following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.051*	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.052*	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.053*	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.054*	Hemiplegia and hemiparesis following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.061*	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right dominant side
I69.062*	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left dominant side
I69.063*	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting right non-dominant side
I69.064*	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage affecting left non-dominant side
I69.065*	Other paralytic syndrome following nontraumatic subarachnoid hemorrhage, bilateral
I69.131*	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right dominant side
I69.132*	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.133*	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.134*	Monoplegia of upper limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.141*	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right dominant side
I69.142*	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.143*	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.144*	Monoplegia of lower limb following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.151*	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right dominant side

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I69.152*	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.153*	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.154*	Hemiplegia and hemiparesis following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.161*	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right dominant side
I69.162*	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left dominant side
I69.163*	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting right non-dominant side
I69.164*	Other paralytic syndrome following nontraumatic intracerebral hemorrhage affecting left non-dominant side
I69.165*	Other paralytic syndrome following nontraumatic intracerebral hemorrhage, bilateral
I69.231*	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right dominant side
I69.232*	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left dominant side
I69.233*	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
I69.234*	Monoplegia of upper limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
I69.241*	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right dominant side
I69.242*	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left dominant side
I69.243*	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting right non-dominant side
I69.244*	Monoplegia of lower limb following other nontraumatic intracranial hemorrhage affecting left non-dominant side
I69.251*	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right dominant side
I69.252*	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left dominant side
I69.253*	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting right non-dominant side
I69.254*	Hemiplegia and hemiparesis following other nontraumatic intracranial hemorrhage affecting left non-dominant side
I69.261*	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right dominant side
I69.262*	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left dominant side
I69.263*	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting right non-dominant side
I69.264*	Other paralytic syndrome following other nontraumatic intracranial hemorrhage affecting left non-dominant side
I69.265*	Other paralytic syndrome following other nontraumatic intracranial hemorrhage, bilateral
I69.331*	Monoplegia of upper limb following cerebral infarction affecting right dominant side
I69.332*	Monoplegia of upper limb following cerebral infarction affecting left dominant side
I69.333*	Monoplegia of upper limb following cerebral infarction affecting right non-dominant side

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I69.334*	Monoplegia of upper limb following cerebral infarction affecting left non-dominant side
I69.341*	Monoplegia of lower limb following cerebral infarction affecting right dominant side
I69.342*	Monoplegia of lower limb following cerebral infarction affecting left dominant side
I69.343*	Monoplegia of lower limb following cerebral infarction affecting right non-dominant side
I69.344*	Monoplegia of lower limb following cerebral infarction affecting left non-dominant side
I69.351*	Hemiplegia and hemiparesis following cerebral infarction affecting right dominant side
I69.352*	Hemiplegia and hemiparesis following cerebral infarction affecting left dominant side
I69.353*	Hemiplegia and hemiparesis following cerebral infarction affecting right non-dominant side
I69.354*	Hemiplegia and hemiparesis following cerebral infarction affecting left non-dominant side
I69.361*	Other paralytic syndrome following cerebral infarction affecting right dominant side
I69.362*	Other paralytic syndrome following cerebral infarction affecting left dominant side
I69.363*	Other paralytic syndrome following cerebral infarction affecting right non-dominant side
I69.364*	Other paralytic syndrome following cerebral infarction affecting left non-dominant side
I69.365*	Other paralytic syndrome following cerebral infarction, bilateral
I69.831*	Monoplegia of upper limb following other cerebrovascular disease affecting right dominant side
I69.832*	Monoplegia of upper limb following other cerebrovascular disease affecting left dominant side
I69.833*	Monoplegia of upper limb following other cerebrovascular disease affecting right non-dominant side
I69.834*	Monoplegia of upper limb following other cerebrovascular disease affecting left non-dominant side
I69.841*	Monoplegia of lower limb following other cerebrovascular disease affecting right dominant side
I69.842*	Monoplegia of lower limb following other cerebrovascular disease affecting left dominant side
I69.843*	Monoplegia of lower limb following other cerebrovascular disease affecting right non-dominant side
I69.844*	Monoplegia of lower limb following other cerebrovascular disease affecting left non-dominant side
I69.851*	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right dominant side
I69.852*	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left dominant side
I69.853*	Hemiplegia and hemiparesis following other cerebrovascular disease affecting right non-dominant side
I69.854*	Hemiplegia and hemiparesis following other cerebrovascular disease affecting left non-dominant side
I69.861*	Other paralytic syndrome following other cerebrovascular disease affecting right dominant side
I69.862*	Other paralytic syndrome following other cerebrovascular disease affecting left dominant side
I69.863*	Other paralytic syndrome following other cerebrovascular disease affecting right non-dominant side
I69.864*	Other paralytic syndrome following other cerebrovascular disease affecting left non-dominant side
I69.865*	Other paralytic syndrome following other cerebrovascular disease, bilateral
I69.932	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left dominant side
I69.933	Monoplegia of upper limb following unspecified cerebrovascular disease affecting right non-dominant side
I69.934	Monoplegia of upper limb following unspecified cerebrovascular disease affecting left non-dominant side
I69.941	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right dominant side
I69.942	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left dominant side
I69.943	Monoplegia of lower limb following unspecified cerebrovascular disease affecting right non-dominant side
I69.944	Monoplegia of lower limb following unspecified cerebrovascular disease affecting left non-dominant side
I69.961	Other paralytic syndrome following unspecified cerebrovascular disease affecting right dominant side
I69.963	Other paralytic syndrome following unspecified cerebrovascular disease affecting right non-dominant side
I69.964	Other paralytic syndrome following unspecified cerebrovascular disease affecting left non-dominant side
I69.965	Other paralytic syndrome following unspecified cerebrovascular disease, bilateral
I97.810*	Intraoperative cerebrovascular infarction during cardiac surgery
I97.811*	Intraoperative cerebrovascular infarction during other surgery

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I97.820*	Postprocedural cerebrovascular infarction during cardiac surgery
I97.821*	Postprocedural cerebrovascular infarction during other surgery
S14.0XXA*	Concussion and edema of cervical spinal cord, initial encounter
S14.0XXD*	Concussion and edema of cervical spinal cord, subsequent encounter
S14.0XXS*	Concussion and edema of cervical spinal cord, sequela
S14.101A*	Unspecified injury at C1 level of cervical spinal cord, initial encounter
S14.101D*	Unspecified injury at C1 level of cervical spinal cord, subsequent encounter
S14.101S*	Unspecified injury at C1 level of cervical spinal cord, sequela
S14.111A*	Complete lesion at C1 level of cervical spinal cord, initial encounter
S14.111D*	Complete lesion at C1 level of cervical spinal cord, subsequent encounter
S14.111S*	Complete lesion at C1 level of cervical spinal cord, sequela
S14.112A*	Complete lesion at C2 level of cervical spinal cord, initial encounter
S14.112D*	Complete lesion at C2 level of cervical spinal cord, subsequent encounter
S14.112S*	Complete lesion at C2 level of cervical spinal cord, sequela
S14.113A*	Complete lesion at C3 level of cervical spinal cord, initial encounter
S14.113D*	Complete lesion at C3 level of cervical spinal cord, subsequent encounter
S14.113S*	Complete lesion at C3 level of cervical spinal cord, sequela
S14.114A*	Complete lesion at C4 level of cervical spinal cord, initial encounter
S14.114D*	Complete lesion at C4 level of cervical spinal cord, subsequent encounter
S14.114S*	Complete lesion at C4 level of cervical spinal cord, sequela
S14.115A*	Complete lesion at C5 level of cervical spinal cord, initial encounter
S14.115D*	Complete lesion at C5 level of cervical spinal cord, subsequent encounter
S14.115S*	Complete lesion at C5 level of cervical spinal cord, sequela
S14.116A*	Complete lesion at C6 level of cervical spinal cord, initial encounter
S14.116D*	Complete lesion at C6 level of cervical spinal cord, subsequent encounter
S14.116S*	Complete lesion at C6 level of cervical spinal cord, sequela
S14.117A*	Complete lesion at C7 level of cervical spinal cord, initial encounter
S14.117D*	Complete lesion at C7 level of cervical spinal cord, subsequent encounter
S14.117S*	Complete lesion at C7 level of cervical spinal cord, sequela
S14.118A*	Complete lesion at C8 level of cervical spinal cord, initial encounter
S14.118D*	Complete lesion at C8 level of cervical spinal cord, subsequent encounter
S14.118S*	Complete lesion at C8 level of cervical spinal cord, sequela
S14.121A*	Central cord syndrome at C1 level of cervical spinal cord, initial encounter
S14.121D*	Central cord syndrome at C1 level of cervical spinal cord, subsequent encounter
S14.121S*	Central cord syndrome at C1 level of cervical spinal cord, sequela
S14.122A*	Central cord syndrome at C2 level of cervical spinal cord, initial encounter
S14.122D*	Central cord syndrome at C2 level of cervical spinal cord, subsequent encounter
S14.122S*	Central cord syndrome at C2 level of cervical spinal cord, sequela
S14.123A*	Central cord syndrome at C3 level of cervical spinal cord, initial encounter
S14.123D*	Central cord syndrome at C3 level of cervical spinal cord, subsequent encounter
S14.123S*	Central cord syndrome at C3 level of cervical spinal cord, sequela
S14.124A*	Central cord syndrome at C4 level of cervical spinal cord, initial encounter
S14.124D*	Central cord syndrome at C4 level of cervical spinal cord, subsequent encounter
S14.124S*	Central cord syndrome at C4 level of cervical spinal cord, sequela
S14.125A*	Central cord syndrome at C5 level of cervical spinal cord, initial encounter
S14.125D*	Central cord syndrome at C5 level of cervical spinal cord, subsequent encounter
S14.125S*	Central cord syndrome at C5 level of cervical spinal cord, sequela
S14.126A*	Central cord syndrome at C6 level of cervical spinal cord, initial encounter
S14.126D*	Central cord syndrome at C6 level of cervical spinal cord, subsequent encounter

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

S14.126S*	Central cord syndrome at C6 level of cervical spinal cord, sequela
S14.127A*	Central cord syndrome at C7 level of cervical spinal cord, initial encounter
S14.127D*	Central cord syndrome at C7 level of cervical spinal cord, subsequent encounter
S14.127S*	Central cord syndrome at C7 level of cervical spinal cord, sequela
S14.128A*	Central cord syndrome at C8 level of cervical spinal cord, initial encounter
S14.128D*	Central cord syndrome at C8 level of cervical spinal cord, subsequent encounter
S14.128S*	Central cord syndrome at C8 level of cervical spinal cord, sequela
S14.131A*	Anterior cord syndrome at C1 level of cervical spinal cord, initial encounter
S14.131D*	Anterior cord syndrome at C1 level of cervical spinal cord, subsequent encounter
S14.131S*	Anterior cord syndrome at C1 level of cervical spinal cord, sequela
S14.132A*	Anterior cord syndrome at C2 level of cervical spinal cord, initial encounter
S14.132D*	Anterior cord syndrome at C2 level of cervical spinal cord, subsequent encounter
S14.132S*	Anterior cord syndrome at C2 level of cervical spinal cord, sequela
S14.133A*	Anterior cord syndrome at C3 level of cervical spinal cord, initial encounter
S14.133D*	Anterior cord syndrome at C3 level of cervical spinal cord, subsequent encounter
S14.133S*	Anterior cord syndrome at C3 level of cervical spinal cord, sequela
S14.134A*	Anterior cord syndrome at C4 level of cervical spinal cord, initial encounter
S14.134D*	Anterior cord syndrome at C4 level of cervical spinal cord, subsequent encounter
S14.134S*	Anterior cord syndrome at C4 level of cervical spinal cord, sequela
S14.135A*	Anterior cord syndrome at C5 level of cervical spinal cord, initial encounter
S14.135D*	Anterior cord syndrome at C5 level of cervical spinal cord, subsequent encounter
S14.135S*	Anterior cord syndrome at C5 level of cervical spinal cord, sequela
S14.136A*	Anterior cord syndrome at C6 level of cervical spinal cord, initial encounter
S14.136D*	Anterior cord syndrome at C6 level of cervical spinal cord, subsequent encounter
S14.136S*	Anterior cord syndrome at C6 level of cervical spinal cord, sequela
S14.137A*	Anterior cord syndrome at C7 level of cervical spinal cord, initial encounter
S14.137D*	Anterior cord syndrome at C7 level of cervical spinal cord, subsequent encounter
S14.137S*	Anterior cord syndrome at C7 level of cervical spinal cord, sequela
S14.138A*	Anterior cord syndrome at C8 level of cervical spinal cord, initial encounter
S14.138D*	Anterior cord syndrome at C8 level of cervical spinal cord, subsequent encounter
S14.138S*	Anterior cord syndrome at C8 level of cervical spinal cord, sequela
S14.141A*	Brown-Sequard syndrome at C1 level of cervical spinal cord, initial encounter
S14.141D*	Brown-Sequard syndrome at C1 level of cervical spinal cord, subsequent encounter
S14.141S*	Brown-Sequard syndrome at C1 level of cervical spinal cord, sequela
S14.142A*	Brown-Sequard syndrome at C2 level of cervical spinal cord, initial encounter
S14.142D*	Brown-Sequard syndrome at C2 level of cervical spinal cord, subsequent encounter
S14.142S*	Brown-Sequard syndrome at C2 level of cervical spinal cord, sequela
S14.143A*	Brown-Sequard syndrome at C3 level of cervical spinal cord, initial encounter
S14.143D*	Brown-Sequard syndrome at C3 level of cervical spinal cord, subsequent encounter
S14.143S*	Brown-Sequard syndrome at C3 level of cervical spinal cord, sequela
S14.144A*	Brown-Sequard syndrome at C4 level of cervical spinal cord, initial encounter
S14.144D*	Brown-Sequard syndrome at C4 level of cervical spinal cord, subsequent encounter
S14.144S*	Brown-Sequard syndrome at C4 level of cervical spinal cord, sequela
S14.145A*	Brown-Sequard syndrome at C5 level of cervical spinal cord, initial encounter
S14.145D*	Brown-Sequard syndrome at C5 level of cervical spinal cord, subsequent encounter
S14.145S*	Brown-Sequard syndrome at C5 level of cervical spinal cord, sequela
S14.146A*	Brown-Sequard syndrome at C6 level of cervical spinal cord, initial encounter
S14.146D*	Brown-Sequard syndrome at C6 level of cervical spinal cord, subsequent encounter
S14.146S*	Brown-Sequard syndrome at C6 level of cervical spinal cord, sequela

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

S14.147A*	Brown-Sequard syndrome at C7 level of cervical spinal cord, initial encounter
S14.147D*	Brown-Sequard syndrome at C7 level of cervical spinal cord, subsequent encounter
S14.147S*	Brown-Sequard syndrome at C7 level of cervical spinal cord, sequela
S14.148A*	Brown-Sequard syndrome at C8 level of cervical spinal cord, initial encounter
S14.148D*	Brown-Sequard syndrome at C8 level of cervical spinal cord, subsequent encounter
S14.148S*	Brown-Sequard syndrome at C8 level of cervical spinal cord, sequela
S14.151A*	Other incomplete lesion at C1 level of cervical spinal cord, initial encounter
S14.151D*	Other incomplete lesion at C1 level of cervical spinal cord, subsequent encounter
S14.151S*	Other incomplete lesion at C1 level of cervical spinal cord, sequela
S14.152A*	Other incomplete lesion at C2 level of cervical spinal cord, initial encounter
S14.152D*	Other incomplete lesion at C2 level of cervical spinal cord, subsequent encounter
S14.152S*	Other incomplete lesion at C2 level of cervical spinal cord, sequela
S14.153A*	Other incomplete lesion at C3 level of cervical spinal cord, initial encounter
S14.153D*	Other incomplete lesion at C3 level of cervical spinal cord, subsequent encounter
S14.153S*	Other incomplete lesion at C3 level of cervical spinal cord, sequela
S14.154A*	Other incomplete lesion at C4 level of cervical spinal cord, initial encounter
S14.154D*	Other incomplete lesion at C4 level of cervical spinal cord, subsequent encounter
S14.154S*	Other incomplete lesion at C4 level of cervical spinal cord, sequela
S14.155A*	Other incomplete lesion at C5 level of cervical spinal cord, initial encounter
S14.155D*	Other incomplete lesion at C5 level of cervical spinal cord, subsequent encounter
S14.155S*	Other incomplete lesion at C5 level of cervical spinal cord, sequela
S14.156A*	Other incomplete lesion at C6 level of cervical spinal cord, initial encounter
S14.156D*	Other incomplete lesion at C6 level of cervical spinal cord, subsequent encounter
S14.156S*	Other incomplete lesion at C6 level of cervical spinal cord, sequela
S14.157A*	Other incomplete lesion at C7 level of cervical spinal cord, initial encounter
S14.157D*	Other incomplete lesion at C7 level of cervical spinal cord, subsequent encounter
S14.157S*	Other incomplete lesion at C7 level of cervical spinal cord, sequela
S14.158A*	Other incomplete lesion at C8 level of cervical spinal cord, initial encounter
S14.158D*	Other incomplete lesion at C8 level of cervical spinal cord, subsequent encounter
S14.158S*	Other incomplete lesion at C8 level of cervical spinal cord, sequela
S24.0XXA*	Concussion and edema of thoracic spinal cord, initial encounter
S24.0XXD*	Concussion and edema of thoracic spinal cord, subsequent encounter
S24.0XXS*	Concussion and edema of thoracic spinal cord, sequela
S24.111A*	Complete lesion at T1 level of thoracic spinal cord, initial encounter
S24.111D*	Complete lesion at T1 level of thoracic spinal cord, subsequent encounter
S24.111S*	Complete lesion at T1 level of thoracic spinal cord, sequela
S24.112A*	Complete lesion at T2-T6 level of thoracic spinal cord, initial encounter
S24.112D*	Complete lesion at T2-T6 level of thoracic spinal cord, subsequent encounter
S24.112S*	Complete lesion at T2-T6 level of thoracic spinal cord, sequela
S24.113A*	Complete lesion at T7-T10 level of thoracic spinal cord, initial encounter
S24.113D*	Complete lesion at T7-T10 level of thoracic spinal cord, subsequent encounter
S24.113S*	Complete lesion at T7-T10 level of thoracic spinal cord, sequela
S24.114A*	Complete lesion at T11-T12 level of thoracic spinal cord, initial encounter
S24.114D*	Complete lesion at T11-T12 level of thoracic spinal cord, subsequent encounter
S24.114S*	Complete lesion at T11-T12 level of thoracic spinal cord, sequela
S24.131A*	Anterior cord syndrome at T1 level of thoracic spinal cord, initial encounter
S24.131D*	Anterior cord syndrome at T1 level of thoracic spinal cord, subsequent encounter
S24.131S*	Anterior cord syndrome at T1 level of thoracic spinal cord, sequela
S24.132A*	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, initial encounter

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

S24.132D*	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, subsequent encounter
S24.132S*	Anterior cord syndrome at T2-T6 level of thoracic spinal cord, sequela
S24.133A*	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, initial encounter
S24.133D*	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, subsequent encounter
S24.133S*	Anterior cord syndrome at T7-T10 level of thoracic spinal cord, sequela
S24.134A*	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, initial encounter
S24.134D*	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, subsequent encounter
S24.134S*	Anterior cord syndrome at T11-T12 level of thoracic spinal cord, sequela
S24.141A*	Brown-Sequard syndrome at T1 level of thoracic spinal cord, initial encounter
S24.141D*	Brown-Sequard syndrome at T1 level of thoracic spinal cord, subsequent encounter
S24.141S*	Brown-Sequard syndrome at T1 level of thoracic spinal cord, sequela
S24.142A*	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, initial encounter
S24.142D*	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, subsequent encounter
S24.142S*	Brown-Sequard syndrome at T2-T6 level of thoracic spinal cord, sequela
S24.143A*	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, initial encounter
S24.143D*	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, subsequent encounter
S24.143S*	Brown-Sequard syndrome at T7-T10 level of thoracic spinal cord, sequela
S24.144A*	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, initial encounter
S24.144D*	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, subsequent encounter
S24.144S*	Brown-Sequard syndrome at T11-T12 level of thoracic spinal cord, sequela
S24.151A*	Other incomplete lesion at T1 level of thoracic spinal cord, initial encounter
S24.151D*	Other incomplete lesion at T1 level of thoracic spinal cord, subsequent encounter
S24.151S*	Other incomplete lesion at T1 level of thoracic spinal cord, sequela
S24.152A*	Other incomplete lesion at T2-T6 level of thoracic spinal cord, initial encounter
S24.152D*	Other incomplete lesion at T2-T6 level of thoracic spinal cord, subsequent encounter
S24.152S*	Other incomplete lesion at T2-T6 level of thoracic spinal cord, sequela
S24.153A*	Other incomplete lesion at T7-T10 level of thoracic spinal cord, initial encounter
S24.153D*	Other incomplete lesion at T7-T10 level of thoracic spinal cord, subsequent encounter
S24.153S*	Other incomplete lesion at T7-T10 level of thoracic spinal cord, sequela
S24.154A*	Other incomplete lesion at T11-T12 level of thoracic spinal cord, initial encounter
S24.154D*	Other incomplete lesion at T11-T12 level of thoracic spinal cord, subsequent encounter
S24.154S*	Other incomplete lesion at T11-T12 level of thoracic spinal cord, sequela

* The diagnosis codes above require a second code from Table 1 in order to be payable.

Appendix D: Conditions for Which Botulinum Toxin Therapy is NOT Reasonable and Necessary

- Skin wrinkles (ICD-10 code L11.8, L57.2, L57.4, L66.4, L87.1, L90.3, L90.4, L92.2, L94.8, L98.5, L98.6)
- Strabismus and deviations over 50 prism diopters
- Restrictive strabismus
- Chronic paralytic strabismus except to reduce antagonist contracture in conjunction with surgical repair
- Duane’s syndrome with lateral rectus muscle weakness
- Recurrent temporomandibular joint (TMJ) disorder
- Anal spasm
- Irritable colon
- Biliary dyskinesia
- Muscle tension
- Tension headaches
- Myofascial pain
- Other forms of smooth muscle spasm not listed as covered in this policy

Any spastic condition not listed as covered in this policy

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by CVS Caremark or the benefit plan sponsor.

X _____
Prescriber or Authorized Signature Date (mm/dd/yy)

Send completed form to: CVS Caremark Specialty Programs. Fax: 1-866-237-5512

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. MR HMSA Medicare Advantage Botulinum Toxins C20381-A, C10947-A – 04/2026.

**CVS Caremark Specialty Programs • 2969 Mapunapuna Place • Honolulu, HI 96819
Phone: 1-808-254-4414 • Fax: 1-866-237-5512 • www.caremark.com**